- Home
- NVGS vs ZYME Comparison
NVGS vs ZYME Comparison
Compare NVGS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- ZYME
- Stock Information
- Founded
- NVGS 1997
- ZYME 2003
- Country
- NVGS United Kingdom
- ZYME United States
- Employees
- NVGS N/A
- ZYME N/A
- Industry
- NVGS Marine Transportation
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- ZYME Health Care
- Exchange
- NVGS Nasdaq
- ZYME Nasdaq
- Market Cap
- NVGS 1.1B
- ZYME 968.5M
- IPO Year
- NVGS N/A
- ZYME 2017
- Fundamental
- Price
- NVGS $16.85
- ZYME $16.49
- Analyst Decision
- NVGS Strong Buy
- ZYME Buy
- Analyst Count
- NVGS 2
- ZYME 7
- Target Price
- NVGS $21.50
- ZYME $20.00
- AVG Volume (30 Days)
- NVGS 270.8K
- ZYME 469.1K
- Earning Date
- NVGS 11-05-2025
- ZYME 10-30-2025
- Dividend Yield
- NVGS 1.19%
- ZYME N/A
- EPS Growth
- NVGS 12.51
- ZYME N/A
- EPS
- NVGS 1.26
- ZYME N/A
- Revenue
- NVGS $566,889,000.00
- ZYME $122,867,000.00
- Revenue This Year
- NVGS $2.20
- ZYME $107.76
- Revenue Next Year
- NVGS N/A
- ZYME $2.35
- P/E Ratio
- NVGS $13.33
- ZYME N/A
- Revenue Growth
- NVGS 1.19
- ZYME 95.94
- 52 Week Low
- NVGS $10.55
- ZYME $9.03
- 52 Week High
- NVGS $17.53
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- NVGS 62.44
- ZYME 68.82
- Support Level
- NVGS $16.43
- ZYME $15.79
- Resistance Level
- NVGS $16.93
- ZYME $16.37
- Average True Range (ATR)
- NVGS 0.32
- ZYME 0.70
- MACD
- NVGS 0.03
- ZYME 0.09
- Stochastic Oscillator
- NVGS 90.65
- ZYME 96.49
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.